海创药业-U
(688302)
| 流通市值：43.27亿 | | | 总市值：43.27亿 |
| 流通股本：9901.56万 | | | 总股本：9901.56万 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 26,025,486.34 | 20,469,871.8 | 23,351,806.02 | 13,167,136.01 |
| 营业收入 | 26,025,486.34 | 20,469,871.8 | 23,351,806.02 | 13,167,136.01 |
| 二、营业总成本 | 61,436,387.58 | 187,696,021.58 | 142,363,467.94 | 85,364,215.91 |
| 营业成本 | 47,435.99 | 282,823.98 | 100,984.3 | 62,643.88 |
| 税金及附加 | 263,012.24 | 901,651.77 | 647,342.45 | 376,732.29 |
| 销售费用 | 21,129,905.81 | 37,691,072.27 | 25,686,625.67 | 10,500,524.53 |
| 管理费用 | 9,821,684.44 | 42,461,694.22 | 32,376,189.72 | 21,421,965.73 |
| 研发费用 | 29,376,274.53 | 112,707,661.3 | 88,764,019.99 | 56,967,171.91 |
| 财务费用 | 798,074.57 | -6,348,881.96 | -5,211,694.19 | -3,964,822.43 |
| 其中:利息费用 | 65,612.3 | 354,105.22 | 279,129.96 | 195,045.1 |
| 其中:利息收入 | 903,014.69 | 8,394,699.98 | 6,614,737.69 | 4,571,463.99 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 950,234.15 | 10,167,088.15 | 5,326,709.35 | 2,054,220.43 |
| 加:投资收益 | 949,696.95 | 5,184,084.25 | 3,055,541.53 | 1,843,351.3 |
| 信用减值损失(新) | -145,692.78 | -704,102.58 | -890,020.49 | -806,540.25 |
| 其他收益 | 4,183,999.93 | 16,219,448.37 | 12,971,810.91 | 7,494,467.56 |
| 四、营业利润 | -29,472,662.99 | -136,359,631.59 | -98,547,620.62 | -61,611,580.86 |
| 减:营业外支出 | 406,197.65 | 889,939.78 | 596,494.84 | 239,605.3 |
| 五、利润总额 | -29,878,860.64 | -137,249,571.37 | -99,144,115.46 | -61,851,186.16 |
| 减:所得税费用 | 3,127.19 | 3,039.88 | 3,048.94 | 2,014.8 |
| 六、净利润 | -29,881,987.83 | -137,252,611.25 | -99,147,164.4 | -61,853,200.96 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -29,881,987.83 | -137,252,611.25 | -99,147,164.4 | -61,853,200.96 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -29,881,987.83 | -137,252,611.25 | -99,147,164.4 | -61,853,200.96 |
| 扣除非经常损益后的净利润 | -35,536,617.22 | -167,871,681.59 | -119,904,731.35 | -73,005,634.95 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.3 | -1.39 | -1 | -0.62 |
| (二)稀释每股收益 | -0.3 | -1.39 | - | - |
| 八、其他综合收益 | -70,018.53 | -117,308.03 | -69,763.02 | -39,554.47 |
| 归属于母公司股东的其他综合收益 | -70,018.53 | -117,308.03 | -69,763.02 | -39,554.47 |
| 九、综合收益总额 | -29,952,006.36 | -137,369,919.28 | -99,216,927.42 | -61,892,755.43 |
| 归属于母公司股东的综合收益总额 | -29,952,006.36 | -137,369,919.28 | -99,216,927.42 | -61,892,755.43 |
| 公告日期 | 2026-04-25 | 2026-04-25 | 2025-10-31 | 2025-08-14 |
| 审计意见(境内) | | 标准无保留意见 | | |